Cefixime Dispersible Tablets 100 mg is an orally active cephalosporin antibiotic that has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms.
It is indicated for the treatment of the following acute infections when caused by susceptible microorganisms:
Upper Respiratory Tract Infections (URTI): e.g., otitis media and other URTIs where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.
Lower Respiratory Tract Infection: e.g., bronchitis.
Urinary Tract Infections: e.g., cystitis, cystourethritis, and uncomplicated pyelonephritis.
Clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens, including Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Klebsiella species, Haemophilus influenzae (beta-lactamase positive and negative), Branhamella catarrhalis (beta-lactamase positive and negative) and Enterobacter species. cefixime dispersible tablets ip 100 mg are highly stable in the presence of beta-lactamase enzymes.
Most strains of enterococci (Streptococcus faecalis, group D Streptococci) and Staphylococci (including coagulase-positive and -negative strains and methicillin-resistant strains) are resistant to cefixime dispersible tablets ip 100 mg. In addition, most strains of Pseudomonas, Bacteroides fragilis, Listeria monocytogenes, and Clostridia are resistant to Cefixime Dispersible Tablets 100 mg.
What are the benefits of cefixime dispersible tablets ip 100 mg
Easy Consumption for Children & Elderly
No Water Needed
Gentle Yet Effective
Encephalopathy
Beta-lactams, including cefixime, predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, and movement disorders), particularly in case of overdose or renal impairment.
Severe cutaneous adverse reactions
Severe cutaneous adverse reactions (SCARS), including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), have been reported in association with cefixime. Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Treatment should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of skin hypersensitivity.
Ceficonex should be given with caution to patients who have shown hypersensitivity to other drugs.
Hypersensitivity to penicillins
As with other cephalosporins, cefixime should be given with caution to patients with a history of hypersensitivity to penicillin, as there is some evidence of partial cross-allergenicity between the penicillins and cephalosporins.
Patients have had severe reactions (including anaphylaxis) to both classes of drugs. If an allergic effect occurs with Ceficonex, the drug should be discontinued and the patient treated with appropriate agents if necessary.
Haemolytic anaemia
Drug-induced hemolytic anemia, including severe cases with a fatal outcome, has been described for cephalosporins (as a class). The recurrence of hemolytic anemia after re-administration of cephalosporins in a patient with a history of cephalosporin- (including cefixime-) associated hemolytic anemia has also been reported.
Acute renal failure
As with other cephalosporins, cefixime may cause acute renal failure, including tubulointerstitial nephritis as an underlying pathological condition. When acute renal failure occurs, cefixime should be discontinued and appropriate therapy and/or measures should be taken.
Renal impairment
Cefixime Dispersible Tablets 100 mg should be administered with caution in patients with markedly impaired renal function.
Paediatric use
Safety of cefixime in premature or newborn infants has not been established.
Antibiotic-associated colitis
Treatment with broad-spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of antibiotic-associated diarrhea. Pseudomembranous colitis is associated with the use of broad-spectrum antibiotics (including macrolides, semi-synthetic penicillins, lincosamides, and cephalosporins); it is therefore important to consider its diagnosis in patients who develop diarrhea in association with the use of antibiotics. Symptoms of pseudomembranous colitis may occur during or after antibiotic treatment.
Management of pseudomembranous colitis should include sigmoidoscopy, appropriate bacteriologic studies, fluids, electrolytes, and protein supplementation. If the colitis does not improve after the drug has been discontinued, or if the symptoms are severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by C. difficile. Other causes of colitis should be excluded.
The usual course of treatment is 7 days. This may be continued for up to 14 days if required.
Eosinophilia, Hypereosinophilia, Agranulocytosis, Leucopenia, Neutropenia, Granulocytopenia, Hemolytic anemia, Thrombocytopenia, Thrombocytosis, Abdominal pain, ,Diarrhoea, Dyspepsia, Nausea, Vomiting, Flatulence, Jaundice, Pseudomembranous colitis, Vaginitis, Aspartate aminotransferase increased
Alanine aminotransferase increased, Blood bilirubin increased, Blood urea increased, Blood creatinine increased, Dizziness, Headache, Cases of convulsions have been reported with cephalosporins, including cefixime (frequency not known). **
Beta-lactams, including cefixime, predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, and movement disorders), particularly in case of overdose or renal impairment (frequency not known). **
Dyspnoea
Acute renal failure with tubulointerstitial nephritis, Anaphylactic reaction, Angio-oedema, Serum sickness-like reaction
Drug rash with eosinophilia and systemic symptoms (DRESS) Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Urticaria, Rash, Pruritus Acute generalised exanthematous pustulosis (AGEP) Drug Fever, Arthralgia, Pyrexia, Face oedema, Genital pruritus
Store below 30°C and protect from light and moisture.
Keep the Cefixime Dispersible Tablets 100 mg out of reach of children.
10 × 10 Alu/Alu Blister.
Cefixime Dispersible Tablets 100 mg are available in an Alu/Alu blister of 10 tablets. Such 10 blisters in a unit carton with a pack insert.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug formulations.
Reduce overall costs and time to market :
Contract manufacturers already have the needed infrastructure and technical staff, so working with a CMO or CDMO can decrease the cost of manufacturing your pharmaceutical products.
Scalability and flexible production capacity :
You can produce what you need when you need it without worrying about excess capacity. Additionally, CMOs understand the importance of quality and compliance, so you don't have to sacrifice safety for scalability.
Save on upgrading and maintaining equipment :
If you have your manufacturing facility, you’ll have to pay to upgrade your equipment as technology advances—which can get expensive. A CMO/CDMO’s only function is to make and distribute products, so part of their core business responsibility is to update their equipment whenever needed and perform maintenance.
Ease supply chain issues :
During the pandemic, there were several instances of supply chain issues, including medicine shortages. CMOs are generally better equipped than startups to handle a supply chain crisis.
Bandwidth to focus on core competencies
When your company resources aren’t directly allocated to manufacturing and distribution, you have more time to focus on other tasks, like marketing your new drug, researching, or working on drug discovery.
We have 7+ manufacturing sites with a minimum of WHO GMP certification and other country-specific approvals like NAFDAC approved, PPK Kenya Approved, TFDA Tanzania Approved, EU-GMP Approved.
We have below manufacturing capacity:
For Tablet, Capsule, and soft gel: up to 1 million units per shift
For Syrup: up to 0.05 Million per shift
For Ampoule and Vial: up to 0.1 million units per shift
For Ointment and Cream: up to 0.1 million units per shift
For Suppository: 0.1 Million units per shift
